- Home
- KXIN vs CANF Comparison
KXIN vs CANF Comparison
Compare KXIN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- CANF
- Stock Information
- Founded
- KXIN 2015
- CANF 1994
- Country
- KXIN China
- CANF Israel
- Employees
- KXIN N/A
- CANF N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- KXIN Consumer Discretionary
- CANF Health Care
- Exchange
- KXIN Nasdaq
- CANF Nasdaq
- Market Cap
- KXIN 13.0M
- CANF 13.5M
- IPO Year
- KXIN N/A
- CANF N/A
- Fundamental
- Price
- KXIN $0.88
- CANF $1.03
- Analyst Decision
- KXIN
- CANF Strong Buy
- Analyst Count
- KXIN 0
- CANF 2
- Target Price
- KXIN N/A
- CANF $14.00
- AVG Volume (30 Days)
- KXIN 93.5K
- CANF 146.4K
- Earning Date
- KXIN 01-01-0001
- CANF 08-29-2025
- Dividend Yield
- KXIN N/A
- CANF N/A
- EPS Growth
- KXIN N/A
- CANF N/A
- EPS
- KXIN N/A
- CANF N/A
- Revenue
- KXIN N/A
- CANF $674,000.00
- Revenue This Year
- KXIN N/A
- CANF $461.72
- Revenue Next Year
- KXIN N/A
- CANF N/A
- P/E Ratio
- KXIN N/A
- CANF N/A
- Revenue Growth
- KXIN N/A
- CANF N/A
- 52 Week Low
- KXIN $0.64
- CANF $0.98
- 52 Week High
- KXIN $29.54
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- KXIN 43.89
- CANF 43.30
- Support Level
- KXIN $0.89
- CANF $1.00
- Resistance Level
- KXIN $1.00
- CANF $1.09
- Average True Range (ATR)
- KXIN 0.07
- CANF 0.03
- MACD
- KXIN -0.00
- CANF 0.00
- Stochastic Oscillator
- KXIN 13.88
- CANF 45.00
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).